AR077455A1 - Preparaciones insulinicas de accion lenta - Google Patents

Preparaciones insulinicas de accion lenta

Info

Publication number
AR077455A1
AR077455A1 ARP100102419A ARP100102419A AR077455A1 AR 077455 A1 AR077455 A1 AR 077455A1 AR P100102419 A ARP100102419 A AR P100102419A AR P100102419 A ARP100102419 A AR P100102419A AR 077455 A1 AR077455 A1 AR 077455A1
Authority
AR
Argentina
Prior art keywords
glu
asp
lys
chemical bond
insulin
Prior art date
Application number
ARP100102419A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR077455A1 publication Critical patent/AR077455A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ARP100102419A 2009-07-06 2010-07-06 Preparaciones insulinicas de accion lenta AR077455A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009031750 2009-07-06
DE102010013133 2010-03-27

Publications (1)

Publication Number Publication Date
AR077455A1 true AR077455A1 (es) 2011-08-31

Family

ID=43428815

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102419A AR077455A1 (es) 2009-07-06 2010-07-06 Preparaciones insulinicas de accion lenta

Country Status (7)

Country Link
US (1) US20120232002A1 (https=)
EP (1) EP2451471A1 (https=)
JP (1) JP5675799B2 (https=)
AR (1) AR077455A1 (https=)
TW (1) TW201113032A (https=)
UY (1) UY32765A (https=)
WO (1) WO2011003823A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) * 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
EA200000453A1 (ru) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2002248464A1 (en) * 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
AU2003268621B2 (en) * 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DK2074141T3 (en) * 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
CN102007143B (zh) * 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
WO2011003820A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
TR201809460T4 (tr) * 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.

Also Published As

Publication number Publication date
JP5675799B2 (ja) 2015-02-25
JP2012532179A (ja) 2012-12-13
WO2011003823A1 (de) 2011-01-13
TW201113032A (en) 2011-04-16
UY32765A (es) 2011-01-31
US20120232002A1 (en) 2012-09-13
EP2451471A1 (de) 2012-05-16

Similar Documents

Publication Publication Date Title
AR077455A1 (es) Preparaciones insulinicas de accion lenta
CO6480996A2 (es) Preparaciones insulinicas que comprenden metionina
JP6987500B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
US10584156B2 (en) Insulin analogues with a glucose-regulated conformational switch
AR070119A1 (es) Derivados de insulina con perfil tiempo / accion extremadamente retardado
ES2365410T3 (es) Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
PE20191716A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
ES2440289T3 (es) Preparación que comprende insulina, nicotinamida y arginina
RU2011119988A (ru) Композиции инсулинов длительного действия
AR070118A1 (es) Nuevos derivados de insulina con perfil tiempo/ accion extremadamente retardado
AR094180A1 (es) Derivados de exendina-4
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
TR201809460T4 (tr) Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2009146883A (ru) Стабильные неводные фармацевтические композиции
RU2015144632A (ru) Терапевтические пептиды
CA2898730A1 (en) Glutamic acid-stabilized insulin analogues
RU2016107610A (ru) Фармацевтическая композиция
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
WO2014015078A1 (en) O-linked carbohydrate-modified insulin analogues
US10995129B2 (en) Non-standard insulin analogues
US20220280614A1 (en) Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations
RU2022119802A (ru) Композиции инсулинов длительного действия
EP3496734B1 (en) Insulin glargine
AR131148A1 (es) Composiciones de insulina de acción rápida (variantes de las mismas)

Legal Events

Date Code Title Description
FB Suspension of granting procedure